Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy

ISSN： 1173-8804

Source： BioDrugs, Vol.23, Iss.2, 2009-06, pp. : 77-91

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor: Current Status and Future Challenges in Cancer Therapy

By Hsu Jerry Y. Wakelee Heather A.

BioDrugs, Vol. 23, Iss. 5, 2009-10 ,pp. : 289-304

Adis International

Access to resources Recommend Favorite

Anticancer Therapy Targeting Telomeres and Telomerase: Current Status

By Parkinson E. Kenneth Minty Fay

BioDrugs, Vol. 21, Iss. 6, 2007-01 ,pp. : 375-385

Adis International

Access to resources Recommend Favorite

Cellular Vehicles for Cancer Gene Therapy: Current Status and Future Potential

By Larisa Pereboeva David T. Curiel

BioDrugs, Vol. 18, Iss. 6, 2004-01 ,pp. : 361-385

Adis International

Access to resources Recommend Favorite

Targeting Mitosis for Anti-Cancer Therapy

By Sudakin Valery

BioDrugs, Vol. 21, Iss. 4, 2007-01 ,pp. : 225-233

Adis International

Access to resources Recommend Favorite

Current Status of Gene Therapy for Rheumatoid Arthritis

By Reinecke J.

BioDrugs, Vol. 11, Iss. 2, 1999-02 ,pp. : 103-114

Adis International

Access to resources Recommend Favorite